Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors

Abstract

Key Points HDACi-mediated differentiation therapy is a potent and molecularly rational treatment strategy in t(8;21) AML.

Keywords

PanobinostatMyeloid leukemiaCancer researchMyeloidHistone deacetylaseEpigenetic therapyLeukemiaMedicineHistone deacetylase inhibitorHistoneBiologyImmunologyDNA methylationGene expressionGeneticsGene

Affiliated Institutions

Related Publications

Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling

Roeland Verhaak , Bas J. Wouters , Claudia Erpelinck-Verschueren +6 more

We examined the gene expression profiles of two independent cohorts of patients with acute myeloid leukemia [n=247 and n=214 (younger than or equal to 60 years)] to study the ap...

2008 Haematologica 355 citations

Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management

Elias Jabbour , Hagop M. Kantarjian

Disease overview : Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm with an incidence of 1–2 cases per 100,000 adults, and accounts for ∼15% of newly diagnosed ca...

2014 American Journal of Hematology 210 citations

Publication Info

Year: 2014
Type: article
Volume: 123
Issue: 9
Pages: 1341-1352
Citations: 131
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

131

OpenAlex

Cite This

APA Style

                            
                                
                                    Michael Bots, 
                                
                                    Inge Verbrugge, 
                                
                                    Benjamin P. Martin
                                
                                et al.
                            
                            (2014). 
                            Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors. 
                            Blood
                            , 123
                            (9)
                            , 1341-1352.
                            https://doi.org/10.1182/blood-2013-03-488114
                        

Identifiers

DOI: 10.1182/blood-2013-03-488114